Alx Oncology Holdings (ALXO) Amortizatization of Intangibles (2022 - 2026)
Alx Oncology Holdings' (ALXO) quarterly Amortizatization of Intangibles came in at $199000.0 in Q1 2026, down 62.17% year-on-year from $526000.0 in Q1 2025, and up 6.99% quarter-over-quarter from $186000.0 in Q4 2025.
Alx Oncology Holdings (ALXO) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Alx Oncology Holdings has disclosed Amortizatization of Intangibles across 5 years of filings, most recently posting $199000.0 for Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $199000.0, down 62.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $915000.0 (down 74.79% YoY), and the FY2025 annual result was $1.2 million, down 73.33% from the prior year.
- Amortizatization of Intangibles came in at $199000.0 for Q1 2026 at Alx Oncology Holdings, up from $186000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $1.9 million in Q4 2023 to a low of -$107000.0 in Q1 2022.
- The 5-year median for Amortizatization of Intangibles is $684000.0 (2022), against an average of $795588.2.
- Across the five-year window, Amortizatization of Intangibles jumped 41150.0% in 2023 and plunged 79.14% in 2025, its largest moves.
- Alx Oncology Holdings' Amortizatization of Intangibles stood at $684000.0 in 2022, then jumped by 175.0% to $1.9 million in 2023, then slumped by 60.82% to $737000.0 in 2024, then tumbled by 74.76% to $186000.0 in 2025, then increased by 6.99% to $199000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $199000.0 (Q1 2026), $186000.0 (Q4 2025), and $219000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Alx Oncology Holdings | 166.27 Mn | 25.95 Mn | - | 199,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 199,000.00 |
| Mar 31, 2026 | 199,000.00 |
| Dec 31, 2025 | 186,000.00 |
| Dec 31, 2025 | 186,000.00 |
| Sep 30, 2025 | 219,000.00 |
| Sep 30, 2025 | 219,000.00 |
| Jun 30, 2025 | 311,000.00 |
| Jun 30, 2025 | 311,000.00 |
| Mar 31, 2025 | 526,000.00 |
| Mar 31, 2025 | 526,000.00 |
| Dec 31, 2024 | 737,000.00 |
| Dec 31, 2024 | 737,000.00 |
| Sep 30, 2024 | 1.05 Mn |
| Sep 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | 1.32 Mn |
| Jun 30, 2024 | 1.32 Mn |
| Mar 31, 2024 | 1.55 Mn |
| Mar 31, 2024 | 1.55 Mn |
| Dec 31, 2023 | 1.88 Mn |
| Dec 31, 2023 | 1.88 Mn |